Brand Name

Idacio

Generic Name
Adalimumab-Aacf
View Brand Information
FDA approval date: July 01, 2023
Form: Kit

What is Idacio (Adalimumab-Aacf)?

IDACIO is a tumor necrosis factor blocker indicated for: Rheumatoid Arthritis .

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study.
Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study.
Journal: Advances in rheumatology (London, England)
Published: March 07, 2025
Comparing adalimumab biosimilars in the clinical practice of psoriatic patients.
Comparing adalimumab biosimilars in the clinical practice of psoriatic patients.
Journal: Italian journal of dermatology and venereology
Published: February 03, 2025
Evaluation of Methods Employed in Establishing Preclinical Similarity of Adalimumab Biosimilars.
Evaluation of Methods Employed in Establishing Preclinical Similarity of Adalimumab Biosimilars.
Journal: Advances in pharmacological and pharmaceutical sciences
Published: December 09, 2024
View All Latest Advances